Atea Pharmaceuticals (AVIR) Interest & Investment Income (2019 - 2026)
Atea Pharmaceuticals (AVIR) posted quarterly Interest & Investment Income of $2.6 million for Q1 2026, up 2376.52% year-over-year from $105712.8 in Q1 2025, and down 84.01% quarter-over-quarter from $16.4 million in Q4 2025.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Interest & Investment Income (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 2376.52% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $23.6 million (down 24.22% YoY), while the FY2025 annual figure was $16.4 million, down 35.76% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.6 million, down from $16.4 million in the prior quarter.
- The five-year high for Interest & Investment Income was $25.1 million in Q4 2024, with the low at -$388000.0 in Q1 2024.
- The 5-year median for Interest & Investment Income is $377000.0 (2023), against an average of $3.6 million.
- Peak annual rise in Interest & Investment Income reached 12977.08% in 2024, while the deepest fall reached 3200.0% in 2024.
- Atea Pharmaceuticals' Interest & Investment Income stood at $171000.0 in 2022, then surged by 174.27% to $469000.0 in 2023, then jumped by 5242.43% to $25.1 million in 2024, then sank by 34.66% to $16.4 million in 2025, then plunged by 84.01% to $2.6 million in 2026.
- Business Quant data shows AVIR's Interest & Investment Income at $2.6 million in Q1 2026, $16.4 million in Q4 2025, and $201000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Atea Pharmaceuticals | 469.90 Mn | 469.90 Mn | - | 2.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.19 Mn |
| Mar 31, 2026 | 2.62 Mn |
| Dec 31, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 5.71 Mn |
| Sep 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 6.64 Mn |
| Mar 31, 2024 | 6.87 Mn |
| Dec 31, 2023 | 7.76 Mn |
| Sep 30, 2023 | 7.86 Mn |
| Jun 30, 2023 | 7.30 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 31, 2022 | 5.59 Mn |
| Sep 30, 2022 | 4.38 Mn |
| Jun 30, 2022 | 1.08 Mn |
| Mar 31, 2022 | 98,000.00 |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 53,000.00 |